Pharminent

US green light for Remicade biosimilar

US regulators have approved Renflexis, a biosimilar referencing Johnson & Johnson’s tumour necrosis factor (TNF) blocker Remicade (infliximab), across all eligible indications. http://www.pharmatimes.com/news/us_green_light_for_remicade_biosimilar_1191717

Filed under: Biosimilar